Cellyan Biotechnology Co., Ltd
No SEC Form 4 filings for $HKPD in the last 30 days.
See all $HKPD insider activity →GoPro (GPRO) to merge with Starman Optical for $285M, expanding into AI data centers. Fly-E (FLYE) reports $19.1M revenue, growing in electric mobility. Cellyan (HKPD) operates in cross-border pharmaceutical e-commerce. VivoSim (VIVS) has $10.1M cash, aided by a $5M milestone from Eli Lilly (LLY).
Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's share price was below $1.00 for 30 consecutive business days. Cellyan Biotechnology Co., Ltd has 180 calendar days to regain compliance, with a potential additional 180-day grace period, and is currently exploring options to address the deficiency.
Hong Kong Pharma Digital (NASDAQ: HKPD) announced that shareholders approved all proposals at its December 12, 2025 annual meeting, including a 10x increase in authorized share capital, a share re-designation, a reverse share split, a share repurchase, and the adoption of an Equity Incentive Plan. Critically, the company's name will change to Cellyan Biotechnology Co., Ltd. Following this news, HKPD stock declined by 4.37%, reflecting a moderate negative market reaction.
Over the past 7 days, alphai's AI scored 1 news story mentioning HKPD (Cellyan Biotechnology Co., Ltd). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent HKPD coverage spans financial news and mergers & acquisitions.
Business model targets growing Chinese cross‑border pharma demand.
Cellyan Biotechnology's failure to meet Nasdaq's minimum bid price may lead to further decline or delisting, increasing risk for investors.
The announcement of a name change and shareholder approvals indicates strategic repositioning but has caused only a modest decline in stock price, suggesting limited short-term trading impact.
alphai scores every news story that mentions HKPD with an AI model for sentiment and relevance, and aggregates insider trades from Cellyan Biotechnology Co., Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
GoPro (GPRO) to merge with Starman Optical for $285M, expanding into AI data centers. Fly-E (FLYE) reports $19.1M revenue, growing in electric mobility. Cellyan (HKPD) operates in cross-border pharmaceutical e-commerce. VivoSim (VIVS) has $10.1M cash, aided by a $5M milestone from Eli Lilly (LLY).
2 min readCellyan Biotechnology Co., Ltd (Nasdaq: HKPD) has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's share price was below $1.00 for 30 consecutive business days. Cellyan Biotechnology Co., Ltd has 180 calendar days to regain compliance, with a potential additional 180-day grace period, and is currently exploring options to address the deficiency.
2 min readHong Kong Pharma Digital (NASDAQ: HKPD) announced that shareholders approved all proposals at its December 12, 2025 annual meeting, including a 10x increase in authorized share capital, a share re-designation, a reverse share split, a share repurchase, and the adoption of an Equity Incentive Plan. Critically, the company's name will change to Cellyan Biotechnology Co., Ltd. Following this news, HKPD stock declined by 4.37%, reflecting a moderate negative market reaction.
2 min read
